Breakthrough Weight-Loss Treatment Shamelessly Suppressed… Until Now!

NeonMind Biosciences Psy-che-delics Discovery Set to Transform this Potential $245 Billion Market (1)

We’re overwhelmed with endless diets, supplements, and meal replacement plans claiming to ensure rapid weight loss. Results are unpredictable—and they rarely last.

What HAS been proven to help in weight loss are mush-rooms. No, not the kind you eat on a salad. We’re talking about the “mind elevating” type.

Until recently the law frowned upon this therapy. All the time lobbyists for the “weight loss” industry worked hard to keep it that way…it’s just not good for their clients’ bottom line. 

But in reality, it’s not what’s on people’s plates…it’s what’s in their heads.

NeonMind Biosciences (CSE:NEON) (OTC:NMDBF) is bringing the first FDA and Health Canada approved psy-che-delic therapeutic to patients struggling with obesity.

January 6, 2022:

NeonMind to Present at H.C. Wainwright Bioconnect Conference

At the Crossroads of Two Explosive Markets

Remember the incredible run in the early days of the “cann-a-bis” craze? Combine the psy-che-delics market projected to reach $6.85 billion, and the weight management market which is estimated to reach a massive $245 billion – and the $22.1 billion cann-a-bis market looks like child’s play.


Source 6

Mike Tyson, US Veterans, and Upstart Politicians are Paving the Path to our Next Revolution.

There is a groundswell of public enthusiasm, shining the light on the potential therapeutic benefits of psy-che-delic medicine. In fact, many localities—particularly in North America—are updating their laws.

On the “front lines” of the psy-che-delic revolution, there’s no shortage of celebrities and household names. Former world heavyweight boxing champion “Iron Mike” Tyson is an advocate for psy-che-delics, evangelizing all over the country.

Mike recently spoke at the largest psy-che-delic medicine business event, Wonderland, held in Miami Florida. “It has made me more creative and helps me focus,” Tyson postulated, “I’m more present as a businessman and entrepreneur. ”


Source 6

Veterans Joining the Fight for Legalization

More than a half-dozen municipalities decriminalized psi-lo-cybin, and combat veterans have become a leading force in the drive to legalize psy-ched-elic medicine. Vets credit them with helping ease the post-traumatic stress, anxiety and depression that are often tied to their experiences in the military.

And thanks to NeonMind Biosciences (CSE:NEON)(OTC:NMDBF), weight management can be added to the list. 

Pennsylvania: the Keystone to Legalization and MASSIVE Fortunes

As support for psy-che-delics therapy grows overwhelming, even the government is getting on board.

A bill was recently introduced in the Pennsylvania House of Representatives called the Public Health Benefits of Psi-lo-cybin Act.

This revolutionary bill would establish a framework for clinical studies of psi-lo-cybin, the active ingredient in magic mush-rooms. It would give researchers some cover for sidestepping cumbersome federal regulations that still categorize the substance as having no accepted medical use despite growing evidence that it does.


This is not an isolated instance. Michigan Sen. Jeff Irwin (D-Ann Arbor) introduced legislation recently that would decriminalize the use of psi-lo-cybin and mes-ca-line — two plants and fungi commonly found in psy-che-delics. 

As you can see it’s getting very hard to ignore the positive research showing the amazing healing properties of psi-lo-cybin.

Now there may be very little holding back successful companies like NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) moving forward.

Why NeonMind Biosciences?

NeonMind Biosciences is on the move with two dr-ug development candidates exploring psi-lo-cybin as a breakthrough approach to treat obesity and promote lasting weight loss.

NeonMind’s first dr-ug candidate employs psi-lo-cybin as an agonist to the serotonin receptor 5-HT2A, which is involved in the hallu-cin-ogenic effect of psy-che-delics. 

The second dr-ug candidate employs psi-lo-cybin as an agonist to the serotonin 5-HT2C receptor, which controls appetite.

Source 1

The company is also working with Dr. C. Laird Birmingham, a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia.  He’ll consult with the company to develop protocols for its Phase 2 Clinical Trial administering psi-lo-cybin to treat obese patients. (14)

NeonMind also just engaged Certara, the global leader in model-informed dr-ug development to provide strategic integrated dr-ug development support for the investigation of NeonMind’s psi-lo-cybin based dr-ug candidates for the treatment of obesity.  (15)

Source 1

NeonMind Biosciences - Already Seeing Significant Success

For one, the company’s proprietary animal data supports psi-lo-cybin efficacy in reducing weight gain.  Two, weight reduction has been seen in a short period of time.  (1)

Three, the novel data strengthens patent applications.

banner 6

Source 1

From here, the company has key anticipated milestones for the year. (1)

Plus, as NeonMind President and CEO Rob Tessarolo notes:

“It is a very exciting time to be in the psy-che-delics industry, which is undergoing rapid expansion. There is a continuous flow of new companies entering the market and each is replete with important research ideas and vying for the conditions necessary to drive growth.  The growing interest in studying psy-che-delic substances coupled with a fresh look from regulatory agencies means some of these substances have the potential to make it to market and help those patients who need innovative new approaches in care. We have established a distinctive focus on developing innovative treatment modalities for people dealing with obesity.” (16)


Psy-che-delic therapy has the potential to institute long term positive behaviors that may impact food intake and other lifestyle changes which affect weight management, and psi-lo-cybin in low doses may help control appetite and satiety. This important element sets us apart from numerous other psy-che-delic companies working to advance research ideas in psy-che-delic.” (16)

Is There a Good Deal of Support for Psy-che-delic Treatments?

As you can see there is plenty of very positive evidence.

NeonMind Biosciences - Already Seeing Significant Success

NeonMind is also commercializing mush-room-infused food products- including products infused with Lion’s Mane, Turkey Tail, Reishi and Cordyceps. 

Additionally, the company launched a coffee eCommerce platform in November 2020 with infused coffees. This platform has immense potential, because people are reportedly craving infused coffees and teas for an “added superfood go-to morning beverage,” according to Yahoo Life.


“Mush-rooms have long been used in Chinese medicine and newer research shows they are the highest dietary source of the antioxidants ergothioneine and glutathione, which help protect the body against the type of damage that can eventually contribute to age-related diseases like cancer, heart disease, Parkinson’s and Alzheimer’s,” says Beth Warren, RDN, author of Secrets of a Kosher Girl. “Mush-room coffees and teas can give anyone a boost, but they may be especially beneficial for those who are dealing with chronic diseases and inflammation.” (Source 22)


Some of the products being offered by NeonMind include: (23)


Rest Blend — A well-balanced coffee infused with Lion’s Mane and Reishi mush-rooms, as well as Ashwagandha and Turmeric.

Energize Blend — Robust coffee infused with Turkey Tail and Cordycep mush-rooms, blended with Holy Basil and Moringa.


Focus Blend – Dark Roast — A well-balanced coffee infused with Lion’s Mane and Reishi mush-rooms, combined with Gotu Kola and Brahmi.

Protect Blend – Medium Roast — A robust coffee infused with Turkey Tail and Cordycep mush-rooms, blended with the Moringa and Amla Berry.

NeonMind Biosciences: Strong Leadership, Strong Results

Successful companies tend to possess common traits, and one of those traits is a strong management team. NeonMind Biosciences certainly has that covered well.


Over 25 years of experience in the pharmaceutical industry. Former President, CEO and Director of Mind Medicine Inc.


Social-entrepreneur advancing the psy-che-delic movement since 2013. Board Chairman Multidisciplinary Association of Psy-che-delic Studies (MAPS) Canada. Co-Founder and Board Member Canadian Psy-che-delic Association. Founder of Liberty Root Therapy Inc.; featured in the award-winning psy-che-delic documentary 'DOSED'.


CFO of Better Plant Sciences Inc. (CSE: PLNT). Serves as Chair of the Audit Committee for Datable. Technology Corp. (TSXV: TTM) Former CFO of Hanwei Energy Services Corp. Former Chair of Governance and member of Audit. Committees at Poydras Gaming Finance Corp. Former President & CEO of Cipher Pharmaceuticals Inc. Former VP, General Manager Celgene US Inflammation & Immunology, and former President Watson Pharmaceuticals Canada.


Serial entrepreneur with over two decades of experience building companies. Recognized in PROFIT Magazine's W100. Co-founder, President and CEO of Better Plant Sciences Inc. Former Director Merus Labs Inc.


Over 30 years of general management experience. Previously the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies. Co-Founder and CEO of Paragon Vitamins and Co-Founder & Partner at Ignite Ventures Studios.


Over 15 years practicing as a securities lawyer. Partner of Owen Bird Law; practice focused on mergers. and acquisitions, corporate finance and securities. Member of the Law Society of New Brunswick since 1997 and a member of the Law Society of British Columbia since 2005.


Dually boarded Neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty member at the University of British Columbia. Founder and Director, Translational Life Sciences Inc.


World renowned eating disorder specialist for over 35 years, who has pioneered several new internationally recognized treatments for eating disorders. Professor at the University of British Columbia, Faculty of Medicine Department of Psychiatry.


PhD in Neuropharmacology, post-doctoral training at Scripps Institute and dr-ug discovery with Novartis. Tenured Faculty member at the Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, UBC. Approved by Health Canada to possess psi-lo-cybin for NeonMind Preclinical trial.

5 Convincing Reasons to Consider NeonMind Biosciences

1 –
2 –
3 –
5 –
6 –
7 –
8 –

Discover More.

Sign up for news on more investor relations.